Scotland Fails To Recommend Orkambi But 'New Medicines Fund' Should Enable Access

The Scottish Medicines Consortium (SMC) on May 9 published advice mirroring that of its neighbor NICE failing to recommend the use of Vertex's Orkambi on the UK's NHS for the treatment of cystic fibrosis. This comes despite positive reimbursement decisions in other European countries. However, Scotland's New Medicines Fund should ensure there is a route available for patients to access the medicine, Vertex believes.